The goal ofthis core is to provide a resource for the comprehensive collection, processing, storage, and selective histological analysis of biospecimens from endometrial cancer patients. This Core will leverage established and extensive infrastructure that is already available through the Siteman Cancer Center.
The first aim of this core will be to better integrate existing efforts to create a centralized resource for the collection, storage, and equitable distribution of biospecimens (tissue, serum, plasma, peripheral blood) and biospecimen-related data from endometrial cancer patients. The Core will also support the collection of normal uterine tissues for use in the current SPORE projects and future translational research. OBBR guidelines for biospecimen storage and processing will be specifically addressed. Quality assurance standards will be used for both histological validation of specimens and molecular integrity of derivative samples. Biospecimens will be made available to authorized translational investigators both within our SPORE program and across other collaborating SPORE institutions. Access, availability, annotation, and tracking of all biospecimens will be managed using caBIG^'"""""""" software applications (i.e. caTissue Suite v1.1), connectivity, and data standards.
The second aim ofthis Core will be to provide a resource for standardized biospecimen processing that will include laser capture microdissection of tissues, tissue microarray construction, and DNA and/or RNA preparation and QA for subsequent molecular analyses.
The third aim of this Core will be to provide expertise in the histopathological and immunohistochemical evaluation of endometrial and related tissues. Each of these activities will support specific projects described in the SPORE application (e.g. microdissection, DNA preparation, and histological evaluation of GOG-210 specimens for Projects 1-3, collection of normal endometrial tissues for Project 2, immunohistochemistry scoring in Projects 1 and 4) and also provide a resource to promote future correlative science studies focused on endometrial cancer prevention, prognosis, and treatment.

Public Health Relevance

The work proposed will lead to both an improved understanding of endometrial cancer biology and new approaches to the detection, prevention and treatment of uterine cancers which will result in reduced cancer morbidity and mortality.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
1P50CA134254-01A1
Application #
7727354
Study Section
Special Emphasis Panel (ZCA1-RPRB-M (M1))
Project Start
2009-09-18
Project End
2012-08-12
Budget Start
2009-09-18
Budget End
2010-08-31
Support Year
1
Fiscal Year
2009
Total Cost
$61,227
Indirect Cost
Name
Washington University
Department
Type
DUNS #
068552207
City
Saint Louis
State
MO
Country
United States
Zip Code
63130
Cosgrove, Casey M; Tritchler, David L; Cohn, David E et al. (2018) An NRG Oncology/GOG study of molecular classification for risk prediction in endometrioid endometrial cancer. Gynecol Oncol 148:174-180
Li, Jing; Xing, Xiaoyun; Li, Daofeng et al. (2017) Whole-Genome DNA Methylation Profiling Identifies Epigenetic Signatures of Uterine Carcinosarcoma. Neoplasia 19:100-111
Jeske, Yvette W; Ali, Shamshad; Byron, Sara A et al. (2017) FGFR2 mutations are associated with poor outcomes in endometrioid endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol 145:366-373
McMeekin, D Scott; Tritchler, David L; Cohn, David E et al. (2016) Clinicopathologic Significance of Mismatch Repair Defects in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study. J Clin Oncol 34:3062-8
Rocconi, Rodney P; Lankes, Heather A; Brady, William E et al. (2016) The role of racial genetic admixture with endometrial cancer outcomes: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol 140:264-9
Goodfellow, Paul J; Billingsley, Caroline C; Lankes, Heather A et al. (2015) Combined Microsatellite Instability, MLH1 Methylation Analysis, and Immunohistochemistry for Lynch Syndrome Screening in Endometrial Cancers From GOG210: An NRG Oncology and Gynecologic Oncology Group Study. J Clin Oncol 33:4301-8
Frolova, Antonina I; Babb, Sheri A; Zantow, Emily et al. (2015) Impact of an immunohistochemistry-based universal screening protocol for Lynch syndrome in endometrial cancer on genetic counseling and testing. Gynecol Oncol 137:7-13
Huang, Yi-Wen; Kuo, Chieh-Ti; Chen, Jo-Hsin et al. (2014) Hypermethylation of miR-203 in endometrial carcinomas. Gynecol Oncol 133:340-5
Powell, Matthew A; Sill, Michael W; Goodfellow, Paul J et al. (2014) A phase II trial of brivanib in recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study. Gynecol Oncol 135:38-43
Wang, Li-Shu; Burke, Carol A; Hasson, Henrietta et al. (2014) A phase Ib study of the effects of black raspberries on rectal polyps in patients with familial adenomatous polyposis. Cancer Prev Res (Phila) 7:666-74

Showing the most recent 10 out of 34 publications